Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis

William, Mridula; Faez, Sepideh; Papaliodis, George N.; Lobo, Ann-Marie

doi:10.1007/s12348-012-0081-y

Cited by 84 publications

(43 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ocular and joint inflammation were successfully controlled after switching to golimumab with concurrent use of methotrexate 68. Similar results were observed in other series 69,70. Miserocchi et al reported that improvement of ocular inflammation may be observed as soon as 2 weeks after initiation of golimumab 70.…”

Section: Systemic Biologic Therapy For Noninfectious Uveitissupporting

confidence: 83%

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis

Pasadhika¹,

Rosenbaum²

2014

BTT

View full text Add to dashboard Cite

Uveitis is one of the leading causes of blindness worldwide. Noninfectious uveitis may be associated with other systemic conditions, such as human leukocyte antigen B27-related spondyloarthropathies, inflammatory bowel disease, juvenile idiopathic arthritis, Behçet’s disease, and sarcoidosis. Conventional therapy with corticosteroids and immunosuppressive agents (such as methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine) may not be sufficient to control ocular inflammation or prevent non-ophthalmic complications in refractory patients. Off-label use of biologic response modifiers has been studied as primary and secondary therapeutic agents. They are very useful when conventional immunosuppressive therapy has failed or has been poorly tolerated, or to treat concomitant ophthalmic and systemic inflammation that might benefit from these medications. Biologic therapy, primarily infliximab, and adalimumab, have been shown to be rapidly effective for the treatment of various subtypes of refractory uveitis and retinal vasculitis, especially Behçet’s disease-related eye conditions and the uveitis associated with juvenile idiopathic arthritis. Other agents such as golimumab, abatacept, canakinumab, gevokizumab, tocilizumab, and alemtuzumab may have great future promise for the treatment of uveitis. It has been shown that with proper monitoring, biologic therapy can significantly improve quality of life in patients with uveitis, particularly those with concurrent systemic symptoms. However, given high cost as well as the limited long-term safety data, we do not routinely recommend biologics as first-line therapy for noninfectious uveitis in most patients. These agents should be used with caution by experienced clinicians. The present work aims to provide a broad and updated review of the current and in-development systemic biologic agents for the treatment of noninfectious uveitis.

show abstract

Section: Systemic Biologic Therapy For Noninfectious Uveitissupporting

confidence: 83%

Update on the use of systemic biologic agents in the treatment of noninfectious uveitis

Pasadhika¹,

Rosenbaum²

2014

BTT

View full text Add to dashboard Cite

show abstract

“…92 The results of a phase III study to assess efficacy and safety of subcutaneous The use of Golimumab in JIA is off-label.…”

Section: Golimumabmentioning

confidence: 99%

Managing juvenile idiopathic arthritis–associated uveitis

Hawkins

Dick

Lee

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…29,30,44,90,146 Most of these studies include patients with Behçet disease, JIA, and HLA-B27+ associated uveitides. Although the results of these initial studies are encouraging, the reported experience on the use of golimumab for uveitis is too scarce to make any conclusions about its efficacy for uveitis.…”

Section: Golimumabmentioning

confidence: 99%